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Using Fludarabine-Based Conditioning
Polina Stepensky,1 Michael Y. Shapira,2 Dmitry Balashov,3 Pavel Trakhtman,3
Elena Skorobogatova,3 Lyudmila Rheingold,2 Rebecca Brooks,1 Shoshana Revel-Vilk,1
Michael Weintraub,1 Jerry Stein,4 Alexey Maschan,3 Reuven Or,2 Igor B. Resnick2In the mid-1990s, we introduced a fludarabine (Flu)-based conditioning regimen for hematopoietic stem cell
transplantation (HSCT) in patients with Fanconi anemia (FA).The aim of this study is to compare Flu-based
conditioning to alternative regimens in patients with FA. Forty-one patients with FA (aged 0.5-31, median,
10.3 years) who underwent allogeneic HSCT were included in this retrospective study. Hospital records
were reviewed for conditioning regimens, engraftment data, and toxicity. The median (range) follow-up
was 32 (0.5-149) months. Flu-based conditioning regimens were used in 24 patients: 17 patients were treated
with alternative conditioning regimens including a radiation-based regimen/cyclophosphamide and busulfan
regimen. The disease-free survival (DFS) after Flu-based regimens is 83% (20/24) versus 35% (6/17) for the
alternative regimens (P5.002). Toxicity was significantly lower in patients who received Flu-based condition-
ing (modified Bearman toxicity score [P 5 .001]). Seven patients received transplants from matched unre-
lated donors without irradiation (5 of whom are currently alive and well). All patients who survived are
disease free and in good clinical condition.We conclude that a combination of fludarabinewith antithymocyte
globulin (ATG) and low-dose cyclophosphamide (Cy) and/or busulfan (Bu) is safe, demonstrates low rejec-
tion rates, and is well tolerated by FA patients.
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Fanconi anemia (FA) is a part of a group of
inherited bone marrow failure disorders that was
initially described in 1927 by Guido Fanconi. FA is
a heterogenous group of diseases with variable
genotypes and phenotypes with defective DNA repair
mechanisms. FA usually manifests clinically with
congenital malformations and with progressive devel-
opment of severe aplastic anemia and myelodysplastic
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6/j.bbmt.2011.01.001The diagnosis of FA is confirmed by chromosome
breakage tests (diepoxybutane-DEB test) and is
supported by identification of a defect in a specific
complementation group and by mutation analysis.
Hematopoietic stem cell transplantation (HSCT) is
the only treatment with a curative potential for the
hematologic manifestations in this severe congenital
disease [1-3]. Early experience with HSCT in the
treatment of FA was unsuccessful because of the basic
molecular defect in these patients: an excessive
sensitivity to cytotoxic agents that led to severe
radiation and chemotherapy-related toxicty, and
consequently, a high rate of treatment-related mortal-
ity (TRM) as well as unusually severe graft-versus-host
disease (GVHD) [4,5]. More recent publications have
presented convincing evidence supporting the use of
reduced-intensity conditioning (RIC) as a preparative
regimen in HSCT of FA patients. More than 10 years
agowe introduced a fludarabine (Flu)-based condition-
ing for HSC and umbilical cord blood transplantation
[6,7] for FA. This approach dramatically improved
the results of FA treatment. Following initial case
reports and a small series [8-10], larger studies were
published that demonstrated a marked decrease in
transplant-related mortality and a significant increase
in disease-free survival (DFS) [11-14].
Table 1. Patients, Transplant, and Graft Characteristics;
Details in Text Body
Group 1 Group 2
Number of patients 17 24
Biol Blood Marrow Transplant 17:1282-1288, 2011 1283BMT for Fanconi AnemiaHere, we present an update from 3 medical centers
on our experience in HSC transplantation for FA
focusing on a Flu-containing preparative regimen in
which no irradiation or T cell depletion was used.Number of BMT 18 28
Age at BMT 10.2
(0.5-17.3)
9
(3.5-30.8)
M:F 8/9 8/16
Congenital abnormalities (>3) 7 11
Hematology
AA 6 3
SAA 8 18
MDS 1 2
AML 2 1
Protocols
Bu8Cy40 3
Cy10 nfTAI5 7
Cy40 fTLI15 1
Bu8Cy60ATG(Fresenius)40 1
Cy20TAI400/500±ATG 5
Bu4Flu150Atgam90 7
Bu2Flu150Atgam90 1
Flu180Cy20ATG(Fresenius)40/C-1H30 8
Flu180Cy20Bu4ATG(Fresenius)40 4
Flu150Cy20ATG(Fresenius)40 3
Flu150TBI200 1
GVHD prophylaxis
CsA (3 mg\kg) only 16 14
CsA + MMF 2MATERIALS AND METHODS
Patient Characteristics
Forty-one patients with FA (16 males, 25 females)
who underwent 46 HSCTs in the 3 participating
medical centers from June 1993 until September
2007 were included in this retrospective study. Clinical
diagnosis of FA was confirmed by DEB test, comple-
mentation group tests, and molecular analysis in
some of the patients. All patients or guardians signed
informed consent. The demographic and clinical
data are presented in Table 1. All patients but 1 were
in the pediatric age group (\21 years). Approximately
half of the patients had more than 3 congenital
abnormalities. At the time of diagnosis, the majority
of patients had severe aplastic anemia (SAA), whereas
6 had clonal disease.Daclizumab (1 mg/kg+4,+14,+28)
CsA (3 mg\kg)+daclizumab
(1 mg\kg+4,+8,+14,+28)
1 7
FK506+MMF(30 mg/kg)+daclizumab
(1 mg/kg+4,+14,+28)
1
Stem cell source
BM 14 16
PBSC 1 5
UCB 1 1
BM + PBSC 1
BM + UCB 2
TNC: average ± SD 6.8 ± 5.0 11.2 ± 13.9
CD34: med (max-min) 8.7 ± 7.6 9.1 ± 8.9
AA indicates aplastic anemia; SAA, severe aplastic anemia;MDS,myelodys-
plastic syndrome; AML, acute myeloid leukemia; Bu8Cy40, busulfan
8 mg/kg; cyclophosphamide, 40 mg/kg; Cy10 nfTAI5, cyclophosphamide10
mg/kg, nonfractionated thoracoabdominal irradiation 500 cGy; Cy40
fTLI15, cyclophosphamide 40 mg/kg, fractionated total lymphoid
irradiation 500 cGy; Bu8Cy60ATG(Fresenius)40, busulfan 8 mg/kg,
cyclophosphamide 60 mg/kg, rabbit antithymocyte globulin 40 mg/kg;
Cy20TAI400/5006 ATG, cyclophosphamide 20 mg/kg, non-fractionated
thoracoabdominal irradiation400-500cGywithorwithout antithymocyte
globulin; Bu4Flu150Atgam90, busulfan 4 mg/kg, fludarabine 150 mg/kg,
horse antithymocyte globulin 90 mg/kg; Bu2Flu150Atgam90, busulfan
2 mg/kg, fludarabine 150 mg/kg, horse antithymocyte globulin 90 mg/kg;
Flu180Cy20ATG(Fresenius)40/C-1H30, fludarabine 150 mg/kg cyclo-
phosphamide 20 mg/kg, rabbit antithymocyte globulin 40 mg/kg or
Campath-1H 30 mg/kg; Flu180Cy20Bu4ATG(Fresenius)40, fludarabine
180 mg/kg cyclophosphamide 20 mg/kg, busulfan 4 mg/kg, rabbit antithy-
mocyte globulin 40 mg/kg; Flu150Cy20ATG(Fresenius)40, fludarabine
150 mg/kg cyclophosphamide 20 mg/kg, rabbit antithymocyte globulin
40 mg/kg; Flu150TBI200, fludarabine 150 mg/kg, total-body irradiation
200 cGy; CsA, cyclosporine A; MMF, mycophenolate mofetil; BM, bone
marrow; PBSC, peripheral blood stem cells; UCB, umbilical cord blood;
TNC, total nucleated cells.Transplant and Donor Characteristics
Wedescribe 2 groups of patients according to their
conditioning regimens. The first group (group 1,
n 5 17) received Flu-free protocols, the second group
(group 2, n 5 24) was conditioned with a Flu-based
protocol. Details are presented in Table 1.
In group 1 (n 5 17) 14 donors were fully matched
family members (12/14 were siblings, 2/14 full
matched parents). Three patients were transplanted
from matched unrelated donors. In group 2 (n 5 24),
16 patients were transplanted from matched family
donors (MFD) (14 of 16 from matched siblings, 1 of
16 from a full matched parent and 1 of 16 from
a matched cousin). Seven patients were transplanted
from a matched unrelated donor (MUD), 2 of 7 were
mismatched in 1 or 2 loci, and 1 of 7 underwent 2
bone marrow transplantations (BMTs) from 2 differ-
ent matched unrelated donors. One patient was trans-
planted from a 2-locus mismatched umbilical cord
blood, developed primary graft failure, underwent
a second haploidentical transplantation as a rescue,
and died from multiorgan failure.
Peripheral blood stem cell (PBSC) donors were
injected subcutaneously with granulocyte colony-
stimulating factor (G-CSF, filgrastim or Neupogen
(Roche, Israel), 5 mg/kg twice daily for 5 days) and mo-
bilized PBSC were collected on days 5 and 6. Bone
marrow (BM) harvesting was performed under re-
gional or general anesthesia from the posterior ileum.
Unmanipulated PBSC and BM served as the source of
stem cells in 6 and 29 patients, respectively; a combina-
tion of BM and PBSC was used in 2 cases, 1 patientunderwent BMT from unrelated umbilical cord blood
(UCB), and in 3 cases, a combination of BM and cord
blood from matched sibling donor was the source of
cells for transplantation (Table 1). All MFD had a neg-
ative DEB test. Both groups were statistically similar
Table 2. Toxicity Grading According to Modified Bearman
Criteria [16]
CNS 1. easily woken somnolence, mild EEG changes,
transient diplopia;
2. heavily somnolence, confusional status, neurologic
impairment, optic neuritis;
3. seizures, coma
Heart 1. mild ECG or X-ray changes, arrhythmias, transient
hypertension;
2. same abnormalities as above but more severe and
requiring treatment;
3. unresponsive cardiac failure.
Lungs 1. asymptomatic X-ray changes;
2. dyspnea and hypoxia (percutaneous O2 saturation
less than 90%) because of disventilation;
3. ARDS, need of mechanical ventilation.
Liver 1. bilirubin 2-5 mg/dL, AST/ALT 80-200 U/L, liver
enlargement <1 in, weight gain <10%;
2. bilirubin >5 mg/dL, AST/ALT >200 U/L, liver
enlargement >1 in, weight gain >10%, ascites;
3. severe VOD, liver failure, coma.
Gut 1. vomiting, diarrhea less than 30 mL/kg, abdominal
pain;
2. hematemezis, melena, diarrhea more than 30 mL/kg
and/or persisting >10 days;
3. ileus.
Kidneys 1. increased creatinine less than twice basal value;
2. increased creatinine more than twice basal value;
3. dialysis.
Bladder 1. macrohematuria;
2. hemorrhagic cystitis;
3. severe hemorrhagic cystitis (>10 days).
Mucosa 1. mild stomatitis;
2. severe stomatitis requiring morphine (15 days);
3. intubation.
ARDS indicates acute respiratory distress syndrome; VOD, veno-
occulsion disease.
1284 Biol Blood Marrow Transplant 17:1282-1288, 2011P. Stepensky et al.regarding participant’s age at transplantation, the
pathology for which the patient was treated, the time
elapsed between diagnosis and BMT, the relationship
and gender of the donor and the patient, the nuclear
cell counts of the graft, and the cell source.
GVHD Prophylaxis and Treatment
The majority of patients (n5 30) received GVHD
prophylaxis with cyclosporine A (CsA) 3mg/kg per day
intravenously as a single agent starting on day21. Two
patients received combined treatment with CsA and
mycophenolatemofetil (MMF) as a part ofGVHDpre-
vention; in 8 cases, daclizumab was given once weekly
starting from day 18 four times in combination with
CsA; and in 1 case, a combination of FK 506 with dacli-
zumab was used. All but 1 patient treated with a Flu-
based preparative regimen received antithymocyte
globulin (ATG), either rabbit ATG-Fresenius 40 mg/
kg or horse ATG (Atgam) 90 mg/kg total dose (in 1
case, MabCampath-1H (Genzyme, Cambridge, MA,
USA) 30mg/kgwas used), whereas non-Flu–based reg-
imens did not include ATG except 3 cases (Table 1).
CsA administration in patients without signs of
GVHD was continued for at least 6 months and was
gradually reduced thereafter.
Acute and chronic GVHD (aGVHD, cGVHD)
were defined using published criteria [15]. Immediately
upon the appearance of signs and symptoms of
GVHD, methylprednisolone (2 mg/kg) and CsA were
administered.
Supportive Treatment
Before transplantation, all patients received
trimethoprim/sulfamethoxazole, acyclovir and allopu-
rinol during the conditioning. Patients were isolated in
rooms equipped with HEPA filters and received a reg-
ular diet. Additional supportive measures, such as total
parenteral nutrition and blood component transfusion,
were administered as necessary. Cytomegalovirus
antigenemia (pp65) or polymerase chain reaction
(PCR) were performed weekly. and in case of reactiva-
tions, preemptive antiviral treatment was started.
Organ toxicity evaluation was performed using
the modified Bearman toxicity score and included 8
organs (central nervous system, heart, lungs, liver, gut,
kidneys, bladder, and mucosa). Toxicities were classified
into 3 grades—mild, moderate, and severe—and were re-
ported from the beginning of the conditioning regimen
until 90days after transplantation (seeTable 2).Events be-
cause of infections or aGVHDwere not included [16,17].
Chimerism Analysis
To assess engraftment, the degree of chimerism
was monitored weekly by donor and host-specific
DNA markers, using male and female amelogenin
gene PCR bands, and by variable number tandem re-peats (VNTR) or Short tandem repeats (STR)-PCR
assay [18,19].
Statistical Methods
Data were analyzed using Microsoft Excel and
MedCalc (MedCalc Software, Mariakerke, Belgium).
Assessments of median, average, standard devia-
tion, and Student’s t-test with 2-tailed distribution
were used as parametric criteria, whereas categoric
data were compared by chi-square or Fisher exact tests.
The probabilities of engraftment and OS were
plotted using the Kaplan-Meier method. The signifi-
cance was estimated by log-rank test and logistic
regression analysis. Chi-square was used to analyze
some survival predictors.RESULTS
Engraftment
Engraftment characteristics are shown in Figure 1.
Following the Flu-based conditioning, the time to en-
graftment was significantly longer: time to an absolute
neutrophil count (ANC) .0.5  109/L for patients
from group 1 or group 2 was 12.6 6 3.6 and 20.3 6 10
days, respectively (P 5 .001): patients from group 1
reached ANC .0.5  109/L earlier than group 2
Figure 1. Probability of achieving (A) ANC.0.5 109/L and (B) plate-
lets .20  109/L in the 2 treatment groups.
Biol Blood Marrow Transplant 17:1282-1288, 2011 1285BMT for Fanconi Anemia(Figure 1A). Similarly, the average time from engraft-
ment to the presence of platelets.20 109/L for group
1 and group 2 was 156 5.6 and 24.46 20 days, respec-
tively (Figure 1B). This difference was not found to be
statistically significant (P5 .09).
Two patients in the Flu group demonstrated pri-
mary graft failure, both after transplantation fromunre-
lated donors. The first 1 was a 21-year-old woman who
was transplanted from a 2 locusmismatched donor. She
developed neutropenic fever and sepsis and died 28 days
after transplantation.The secondwas a 3.5-year-old girl
who rejected her first graft, restored her own hemato-
poiesis, and 120 days after the first transplantation was
retransplanted fromanotherMUDfollowing a regimen
containing Flu, busulfan, andMabCampath.Currently,
120 months after transplantation, she is alive and clini-
callywell. All engrafted patients demonstrate long-term
100% donor chimerism.Toxicity
Toxicity was related to the type of protocol used.
The grade of toxicity was lower among those ingroup 2: the cumulative toxicity score in group 1,
was 10.6 6 1.4, whereas the average toxicity score
among patients from group 2 was 3.96 0.8 (P5 .001).
This differencewas statistically significant for all or-
gans (P\\ .05) except for the central nervous system
(CNS) and gut (in which the difference was seen but
was not found to be statistically significant). In group
1, the most frequent toxicities were reported to be re-
lated to mucosa, kidneys, and bladder (Table 3). The
number of proven infections was lower in the second
group (P 5 .026 in the t-test) despite a later ANC en-
graftment, probably because of lower mucosal toxicity.Acute GVHD
In the first group, 14 of 17 patients (82%) devel-
oped aGVHD grade 2-4, 8 of them (47%) grade 3-4.
In the second group, 11 of 24 patients (46%) developed
aGVHD grade 2 or more; of them, only 1 developed
grade 3, and none developed grade 4; these differences
were statistically significant (P 5 .015).
A strong association was found between the type of
conditioning protocol used and both the development
of aGVHD, as well as the grade of the GVHD: there
was a lower prevalence of severe GVHD in patients
who received the Flu-based conditioning (P 5 .002;
Table 4).
Comparison of aGVHD prevalence in groups
excluding patients who received daclizumab demon-
strates that the prevalence and severity (P 5 .001 and
P5 .005 accordingly; chi-square test) of this complica-
tion are still lower in group 2. Moreover, when
comparing the subsets of patients within group 2
between those who received daclizumab and those
who did not, it was found that both the prevalence
and the severity of GVHD in the subgroup that
received daclizumab was higher (P 5 .043 and
P 5 .059, both in the Fisher exact test).Chronic GVHD
Chronic GVHD was diagnosed in 36.7% patients
(extensive in 6.7%). In group 1, 4 of the 6 patients
(66%) who survived suffered from cGVHD, 2 of
whom suffered from the extensive form. In group 2,
development of cGVHD was observed in 8 of the 20
survivors (40%), and only 2 of them experienced
extensive disease (NS).
No statistically significant differences were found
between the groups, neither in the rate nor in the
severity of the cGVHD (30 valuable patients).Overall survival (OS)
A profound difference in OS (which was equal to
DFS) was found between the 2 study groups. In group
1, 6 of the 17 patients (35%) survived compared to 20
of the 24 patients (83%) in group 2 (P 5 .002).
Table 3. Comparative Toxicity by Grade for Each Organ of 2 Treatment Groups
CNS Heart Lungs Liver Gut Kidneys Bladder Mucosa Cumulative Toxicity
Group 1 1.13 1. 1.33 1.50 1.14 1.53 1.33 2.13 10.6
Group 2 0.39 0.27 0.30 0.61 0.87 0.35 0.14 0.83 3.9
P (t-test) .094 .050 .018 .020 .25 .002 .004 .004 .001
1286 Biol Blood Marrow Transplant 17:1282-1288, 2011P. Stepensky et al.The odds ratio (OR) for OS in group 1 was 0.289
(95% confidence interval [CI]: 0.099-0.83) compared
to group 2. Kaplan-Meier survival estimates are mod-
eled in Figure 2. GVHD prophylaxis protocol in itself
was not associated with increased survival rate and CsA
alone or in combination with methotrexate, and
anti-CD25 mAb showed similar long-term survival.
Causes of death in group 1were transplant related in
10 out of 11 patient: in 8 cases death resulted from
aGVHD-related causes, 1 death from cGVHD-related
cause (bronchiolitis obliterans), 1 patient developed
a secondary malignancy, and 1 patient died on day 11,
before engraftment, from sepsis and multiorgan failure.
In group 2, two patients died from sepsis, 1 from
toxicity, and 1 from cGVHD; these 4 deaths were con-
sidered transplant-related mortality.
BMT from MUD
In long-term follow-up posttransplant, 5 of the 7
(71%) patients that underwent BMT from MUD are
alive and well with normal blood counts and full donor
chimerism. Two died (a 3-year-old girl with multiple
congenital anomalies and a 21-year-old woman who
was transplanted from a 2-loci mismatched donor).
All these patients underwent BMT after Flu-based
conditioning without use of irradiation, and all but 1
were conditioned with a regimen containing Flu, cyclo-
phosphamide, and a relatively small dose of busulfan.DISCUSSION
Flu-based regimens for HSC transplantation for
FA were introduced at the Hadassah-Hebrew
University Medical Center in the mid-1990s. The firstTable 4. Evidence of Acute and Chronic GVHD in the 2 Treatmen
Group 1 (n 5 17)
Time (days) from transplantation to acute
GVHD (mean ± standard deviation)
23.6 ± 17.2
Acute GVHD grade (patients number)
0 1
1 2
2 4
3 2
4 6
Chronic GVHD grade (patients number)
No 2
Limited 2
Extended 2
NS indicates nonsignificant; GVHD, graft-versus-host disease.cases were described by Kapelushnick et al. (successful
HSCT) [6] and Aker et al. (successful related UCB) [7]
followed by expanding patient series reported both
from our center [8,9,20] and others [10,21,22].
Recently, larger series were published [23-26], all of
them presenting different aspects of the benefit in
the use of Flu-based conditioning for FA patients.
Here, we present a retrospective analysis of our
experience with BMT for FA, which clearly demon-
strates that Flu-ATG–based protocols give signifi-
cantly better results. There are three major
advantages to this regimen.
These protocols are significantly less toxic than
others, in particular compared to irradiation-based
treatments. Because of the tendency of FA patients to
develop excessive organ toxicities during chemotherapy
that could result in death, there are major limitations
providing either transplantation or chemotherapy in
these patients. A far better tolerance to Flu compared
to other immunosuppressive or cytoreductive agents
was shown indifferentBMTsettings.Unlike cyclophos-
phamide or irradiation, Flu does not cause DNA cross-
linking, which is not effectively controlled in FA, and
therefore has a significant role in conditioning in these
patients [27-29]. As shown recently in an in vitro study
by Yabe et al. [30], unlike the majority of chemothera-
peutic agents,Flu hadno influenceon inducedbreakage,
even compared to spontaneous breakage. This explains
the improved tolerability of Flu by patients with FA, as
shown in all recent published series as well as in our
current study. The resulting reduced toxicity during
the conditioning regimen can explain the improved tol-
erability of the transplantation with a significantly
higher OS and a lower rate of GVHD (an epiphenome-
nonassociatedwith infectious complications and qualityt Groups
Group 2 (n 5 24) P Value
34.4 ± 17.5 NS
(Student test)
13
4 .002
5 (chi-square test)
1
0
10 NS
6 (chi-square test)
2
Figure 2. Probability of survival among patients with Fanconi anemia.
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conditioning should be highly considered when BMT
is required for other chromosomal fragility syndromes
such as dyskeratosis congenita and Nijmegen breakage
syndrome.
Patients with FA have a higher rate of aGVHD and
cGVHD post-BMT, resulting in increased morbidity
and mortality compared to other patients. A review
of recent papers shows that T cell–depleted grafts are
used for GVHD prophylaxis even in cases of 100%
matched donors [10]. Our experience shows that
both in the setting of matched family donors as well
as in matched unrelated donors, the incidence of
GVHD is dramatically lower in patients who received
drug-based GVHD prophylaxis without in vitro T cell
depletion. In addition to the substitution of higher
doses of cyclophosphamide and irradiation with Flu,
our protocol incorporated ATG as a part of the
conditioning. The role of ATG in RIC regimens is still
unclear. On the one hand, ATG causes host immuno-
suppression, which can improve engraftment, and in
FA, can be used even as a single agent for a second
BMT [31]. On the other hand, ATG remains in the cir-
culation for several days, therefore causing partial in
vivo donor T cell depletion, and possibly providing ad-
ditional protection from GVHD [32,33]. In addition,
we found that engraftment after Flu-based protocols
was significantly slower. By definition, this means
that there is a lower grade of cytokine production
and a lower incidence of cytokine storm and engraft-
ment syndrome, which can trigger aGVHD develop-
ment [34].This may be an additional explanation to
the lower incidence of GVHD compared with the
other protocols. Previous studies demonstrated that
the addition of anti-CD25 antibodies to standard
anti-GVHD prophylaxis does not improve OS and
does not decrease the rate of aGVHD, probably by
elimination of CD25-positive T-regulatory cells [35].
This is consistent with our current analysis in which
we found that the addition of daclizumab to thetraditional prophylaxis with CsA does not reduce the
rate of GVHD.
Another point worth emphasizing is the ability to
eliminate irradiation even in cases of MUD. A few
studies have shown that in Flu-based conditioning,
stable engraftment can be achieved without the need
of radiation [36,37]. Our data supports these findings.
In summary, the combination of Flu with ATG
and low-dose cyclophosphamide and/or busulfan re-
sults in improved long-termOS and in a lower compli-
cation rate in patients transplanted for FA. Regimens
containing busulfan (4 mg/kg) or cyclophosphamide
(20 mg/kg) demonstrate similar toxicities and engraft-
ment rates, whereas irradiation-based regimens should
be avoided in FA.
In conclusion, our study demonstrates three impor-
tant points. First, use of Flu-ATG–based protocols dra-
matically improves OS with low rejection rates and
excellent toxicity profile, and can therefore be strongly
recommended for allogeneic transplantation for FA. Sec-
ond, elimination of irradiation in the setting of MUD
seems feasible when using Flu-ATG–based protocols,
thus achieving stable engraftment without excessive tox-
icity. And finally, it seems that augmentation of GVHD
prophylaxis with additional modalities, such as T cell de-
pletion or combination with daclizumab and methotrex-
ate (MTX), gives no advantage over the CsA and ATG
regimen, either in the effect on the rate or the severity
of GVHD. We therefore suggest that CsA in combina-
tion with ATG-containing regimens may be sufficient
in prevention of GVHD, especially in cases of transplan-
tation from MFD. Development of Flu-based protocol
details, such as comparing busulfan versus cyclophospha-
mide, details of GVHDprophylaxis, reduction of the Flu
dose, and the type and dose of ATGused, is still an actual
immediate goal. Additional trials for elimination of
irradiation as a part of conditioning in the setting of
MUD warrant further investigation in larger groups
of patients.ACKNOWLEDGMENTS
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